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Abstract
Several studies have reported low brain serotonin transporter (SERT) binding in individuals with 
major depression. We hypothesized that the SERT standardized uptake ratio (SUR) values using 
[123I]-ADAM single photon emission computed tomography would increase in depressed subjects 
who responded to cognitive behavior therapy (CBT) compared to CBT nonresponders. [123I]-
ADAM scans were acquired before and after 12 weeks of CBT from 20 depressed subjects and on 
two occasions 12 weeks apart from 10 non-depressed, healthy volunteers. The primary outcome 
measure was change over time in SUR values in the midbrain, medial temporal lobe, and basal 
ganglia regions. Depressed subjects demonstrated low pre-treatment mean SUR values that 
significantly increased over time in the midbrain (p=0.011), right medial temporal lobe (p=0.008), 
and left medial temporal lobe (p=0.000) regions. Treatment responders showed a significant 
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increase over time in SUR values in left medial temporal lobe (p=0.029) and right medial temporal 
lobe (p=0.007) regions. Partial and nonresponder subjects also showed a significant increase over 
time in SUR values in the left medial temporal region (p=0.040) (versus healthy volunteers), but to 
a lesser degree. The findings suggest that low pre-treatment SERT binding may increase over time 
in some depressed individuals who experience symptom improvement.
Introduction
Several studies have demonstrated low serotonin transporter (SERT) binding in specific 
brain regions of depressed individuals.1-9 For example, Malison et al.1 and Eggers et al.6 
found low SERT binding in depressed subjects using [123I]-β-CIT, a non-selective SERT 
and dopamine transporter radioligand using single photon emission computed tomography 
(SPECT). However, these observations have not been universally observed.10-15 For 
example, Reivich et al.13 used the selective SERT radioligand, [11C](+)McN5652 and 
positron emission tomography (PET) and found greater SERT binding in the temporal lobe 
region of depressed subjects (versus healthy volunteers). In contrast, other investigators 
using [11C](+)McN5652 have reported low SERT binding in depressed subjects.5,15 In 
addition, Ruhé et al.8 reported low midbrain SERT binding in depressed males (versus 
healthy volunteers) using [123I] β-CIT SPECT; while Kalbitzer et al.16 found no difference 
in SERT binding in depressed (versus healthy) women, and an increase in midbrain SERT 
binding in the winter (versus other seasons).
We previously used the selective radioligand 123I-labeled ((2-((dimethylamino)methyl) 
phenyl)thio)-5-iodophenylamine) ([123I]-ADAM) to examine brain SERT binding in 
depressed individuals.3 In a preliminary study of 7 depressed subjects and 6 healthy 
volunteers, we reported low midbrain SERT binding in depressed (versus healthy) subjects 
(p=0.01).3 More recently, we replicated these findings in a new cohort of 20 depressed 
subjects versus 10 healthy volunteers17 - although other [123I]-ADAM studies have not 
substantiated these findings.18,19
The current study examines the change over time in SERT binding standardized uptake ratio 
(SUR) values before and after treatment with cognitive behavior therapy (CBT) in drug free 
depressed subjects. We compared these results with SUR values obtained from untreated, 
healthy volunteers studied with other [123I]-ADAM SPECT on two separate occasions. We 
hypothesized that reduced SUR values would increase over time in treatment responders and 
would show little or no change over time in partial or nonresponders.
Materials and Methods
Informed Consent
Subjects provided written informed consent in accordance with the ethical standards of the 
Institutional Review Board (IRB) of the University of Pennsylvania. The study was 
conducted under IND #65,542 for [123I]-ADAM using Good Clinical Practice guidelines 
with oversight by the local Office of Human Research and an independent Data & Safety 
Monitoring Board.
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Subjects
Outpatient subjects ≥18 years old with a DSM IV-TR Axis I diagnosis of major depressive 
disorder (single or recurrent episode) were enrolled. Subjects were self-referred from IRB-
approved media advertisements. The diagnosis was verified using the Structured Clinical 
Interview for the DSM-IV-TR format.20 Subjects were drug free ≥ 12 months, and had a pre-
treatment 17-item Hamilton Depression Rating (HAM-D) 21 total score ≥16. Subjects 
underwent a physical examination and laboratory evaluation, and were in good health 
without meaningful medical conditions or laboratory abnormalities. Women of child-bearing 
potential had a negative pregnancy test. Subjects were excluded from the study if they met 
any of the following criteria: participant in prior [123I]-ADAM study; primary Axis I 
diagnosis other than major depressive disorder; history of mania or psychosis; actively 
suicidal; substance abuse or dependence within the preceding 3 months; positive screen for 
illicit drugs; unstable medical condition; pregnant or nursing; or history of transient 
ischemic attack, cerebral infarction, hypertensive encephalopathy, intracranial hemorrhage, 
closed head trauma with loss of consciousness, encephalitis, neurotoxin exposure, normal 
pressure hydrocephalus, brain tumor, basal ganglia disease, polyneuropathy, or unable to 
provide informed consent.
Healthy volunteers were recruited from IRB-approved media advertisements. The purpose 
of including this control group was to demonstrate the natural variability in [123I]-ADAM 
uptake over time and to compare this value with the change over time in SERT binding 
observed in depressed subjects. Healthy subjects were ≥18 years old, had no current DSM 
IV-TR Axis I disorder (verified using the SCID format), and had a baseline total HAM-D 
score ≤6. None of the healthy volunteers had any clinically meaningful medical conditions 
or laboratory abnormalities.
Imaging Procedures
Depressed subjects underwent [123I]-ADAM scanning sessions on two separate occasions 
approximately 12 weeks apart: prior to initiating CBT and within 2 weeks of completing 
CBT. Healthy volunteers also underwent two separate [123I]-ADAM scanning sessions 
approximately 12 weeks apart. [Note – Two depressed subjects prematurely discontinued 
CBT and had their post-CBT scanning session performed at week 9 of the study. To 
comport with this time frame, two healthy volunteers also underwent their second scanning 
session at week 9 of the study].
At each scanning session, subjects were administered 18 drops of concentrated Lugol’s 
solution in order to block 123I uptake by the thyroid gland. [123I]-ADAM 185 MBq (5 mCi) 
was injected through an intravenous catheter. Four hours after [123I]-ADAM administration, 
SPECT images were acquired over 60 minutes. Prior kinetic modeling with [123I]-ADAM 
indicated that the 4-hour delay in image acquisition allowed for the use of the reference 
region method for estimating SERT binding, without the need for arterial sampling.22
Image Analysis
SPECT images were analyzed using previously validated methods.23 Images were 
reconstructed using a low pass filter and attenuation correction. All scans were re-sliced in 
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the same plane using oblique reformatting. Manual demarcation of the region of interest 
(ROI) was then performed on the baseline scans focusing on the basal ganglia, midbrain, 
and medial temporal lobe regions – as these were the regions with low SERT binding from 
our prior 123I]-ADAM studies. Standardized templates containing ROIs were fit on each 
scan using previously reported techniques.3 These templates were originally developed 
using anatomically defined regions based on a magnetic resonance imaging atlas of ROIs. 
Within the x-y plane, the ROIs in the template are smaller than the actual structures they 
represent in order to minimize resolution induced problems with ill-defined edges. To 
reduce the effects of volume averaging in the axial direction, the small ROIs were not placed 
on the slices that contained the upper most and lower most portions of the structures they 
represented. This limits the small ROIs to the central aspect of the structures they 
represented. The ROIs are therefore placed on the pre-treatment scans within each brain 
structure in order to obtain the mean counts per voxel. ROIs were then directly placed onto 
the post-treatment scans since all scans were oriented and sliced in the same manner. All 
ROIs were placed by an expert in nuclear medicine image interpretation and analysis who 
was blinded to the diagnosis and treatment status.
The primary imaging outcome measure was the SUR value at 4 hours post [123I]-ADAM 
injection, when the distribution of [123I]-ADAM approached a near equilibrium state that 
reflected the ratio of k3/k4, which was related to [123I]-ADAM binding potential. The SUR 
value was calculated as the ROI ÷ reference region where the reference region was the 
cerebellum which consists of non-specific binding, as described previously.22 [Note - 
Statistical Parametric Mapping (SPM) and other approaches to image analysis were 
considered. However, we chose the ROI technique because it has previously demonstrated 
highly accurate values in quantifying [123I]-ADAM binding in humans.3,17,22,23 This 
procedure allowed us to compare [123I]-ADAM uptake in the target regions to uptake in 
regions of non-specific [123I]-ADAM binding, and to calculate individual SUR values. 
Moreover, since the region of [123I]-ADAM uptake is quite specific, we would have needed 
to use the ROI tool contained in the SPM program for our calculations. In addition, a voxel 
by voxel analysis would not have yielded additional information because [123I]-ADAM 
binds to only a limited number of brain structures].
CBT Procedures
Treatment was conducted by a senior therapist at the Center for Cognitive Therapy at the 
University of Pennsylvania. CBT was administered in a structured fashion according to 
Beck et al.24, and consisted of a series of active directive sessions targeted at promoting 
behavioral activation and counter-acting maladaptive cognitive biases. As CBT progressed, 
the emphasis shifted to identification and evaluation of underlying beliefs and schemas. 
There was an emphasis on cognitive-behavioral skills-training (including homework 
assignments) designed to allow individuals to gain more independent functioning as their 
own ‘therapists’ by the end of treatment. These strategies were supplemented by techniques 
developed to prevent relapse following response to CBT.25 Within this framework, CBT 
was provided in a flexible fashion as determined by the needs of the individual. Sessions 
were scheduled twice weekly during the initial 4 weeks (when possible) and weekly 
thereafter through week 12. Sessions typically lasted 50 minutes.
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Outcome Measures
The primary outcome measure was the change over time in mean SUR values of the 
midbrain, medial temporal lobe, and basal ganglia regions in CBT responders versus healthy 
volunteers compared to CBT partial and nonresponders versus healthy volunteers. Response 
was defined as ≥ 50% reduction in baseline total HAM-D score. Partial and nonresponse 
was defined as < 50% reduction in baseline total HAM-D score.
Statistical Procedures
Analyses were implemented with the realization that the limited sample size may only allow 
for the detection of large differences between groups. All analyses were conducted using 
Stata 11.0 (College Station, TX) with two-sided tests of hypotheses and a p-value <0.05 as 
the criterion for statistical significance. Analyses included means, medians, ranges, and 
standard deviation (SD) of continuous covariates (e.g. age) and SUR values. The ‘sktest’ 
procedure in Stata was used to assess the normality of SUR values for each ROI. The intra-
subject association of SUR values was estimated using the Spearman rank correlation 
coefficient test for each ROI.
T-tests and non-parametric Wilcoxon rank sum tests were used to compare the change over 
time in mean SUR values for depressed subjects and for depressed subjects versus healthy 
volunteers. ANOVA was used to compare the change over time in mean SUR values before 
and after CBT in responders versus partial and nonresponders (relative to the change over 
time in mean SUR values in healthy volunteers). Where significant differences occurred in 
the change over time in SUR values between depressed and healthy subjects, post hoc group 
comparisons were examined using the Scheffe multiple comparison test.
Sample Size Justification
Sample size calculations for the primary study outcome was conducted using Nquery 
Advisor sample size software and Diggle et al.26 to obtain estimates that could be used to 
power a larger follow up study. Preliminary analyses yielded mean (SD) SUR values of 1.81 
(0.07) and 1.95 (0.13) in depressed and healthy subjects, respectively. Assuming a common 
SD of 0.10 would yield an effect size difference of |1.81 − 1.95|/0.10 = 1.40. A sample size 
of 20 depressed subjects versus 10 healthy volunteers would have 80% power to detect an 
effect size of 1.124 using a two group t-test with a 0.05 two-sided significance level.
Results
Enrollment
We examined 20 depressed subjects and 10 healthy volunteers. There were no screen 
failures. Demographic and clinical characteristics of the subject cohorts are displayed in 
Tables 1 and 2. Ten depressed subjects (2 women) were drug naïve and 10 (5 women) 
previously received 3.0 (2.0) (range 1 - 10) antidepressant treatments over the course of their 
illness.
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Baseline SUR Values
Depressed subjects demonstrated significantly lower SUR values for the midbrain 
(p<0.005), right medial temporal lobe (p<0.0005), left medial temporal lobe (p<0.004), right 
basal ganglia (p<0.03), and left basal ganglia (p=0.016) regions (versus healthy 
volunteers).17 There was no effect of age, gender, illness duration, prior antidepressant drug 
exposure, or symptom severity on mean baseline SUR values.17
Change in Mean SUR Values
Overall, depressed subjects demonstrated a significant increase in mean SUR values for the 
midbrain (p=0.011), right medial temporal lobe (p=0.008), and left medial temporal lobe 
(p=0.0001) regions versus healthy volunteers (Table 3). Healthy volunteers demonstrated a 
modest (albeit non-significant) decrease over time in mean SUR values after repeated [123I]-
ADAM testing (Figure 1 and Table 3).
Change in Mean SUR Values Relative to Treatment Response
ANOVA demonstrated significant group differences over time in mean SUR values for the 
left medial temporal lobe (p=0.029) and right medial temporal lobe (p=0.007) regions, and a 
small (albeit non-significant) difference for the midbrain region (p=0.076) (Table 4). Scheffe 
post hoc tests showed a significant increase over time in mean SUR values for treatment 
responders (versus healthy volunteers) for the right medial temporal lobe (p=0.029) and left 
medial temporal lobe (p=0.012) regions. Scheffe test also showed a significant increase over 
time in mean SUR values for partial and nonresponders (versus healthy volunteers) for the 
left medial temporal lobe region (p=0.040) (Table 3). [Note - Some depressed subjects 
classified as partial and nonresponders demonstrated a clinically meaningful reduction in 
total HAM-D scores, but failed to achieve the criterion for ‘response’].
Adverse Events
There were no serious adverse events. Five subjects did experience tingling at the site of 
[123I]-ADAM injection. Thirteen subjects reported an unusual taste and 15 subjects reported 
unusual smell after 123I-ADAM injection, which dissipated within one minute.
Discussion
We previously reported significantly lower baseline mean SERT binding levels in the 
midbrain, medial temporal lobe, and basal ganglia regions of drug free depressed subjects 
(versus healthy volunteers) using [123I]-ADAM.3,17 These findings support other studies 
showing low SERT binding in depressed subjects using other SERT radioligands (e.g., 
[123I]-β-CIT)1,2,4-9 - although this has not been a universal observation.11-14 In the current 
study, we examined the effects of treatment outcome on SERT binding in depressed 
subjects. We selected CBT as a non-pharmacological treatment intervention that would not 
directly affect SERT binding.
Several studies have examined the relationship of SERT binding to treatment response with 
selective serotonin reuptake inhibitor (SSRI) antidepressants. In general, these studies have 
reported a significant reduction in baseline SERT binding during SSRI treatment.18,27 For 
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example, Kugaya et al.11 used [123I] β-CIT to examine the relationship between baseline 
SERT binding and response to fluoxetine therapy in 23 depressed subjects and found a 
significant relationship after 4 weeks of treatment (β=9.30; p=0.028), but not after 6 weeks 
of treatment (β=2.22; p=0.42). Similar results were reported in 10 depressed subjects treated 
with paroxetine.11 Hsieh et al.28 used [123I]-ADAM to examine SERT binding in 13 drug 
free subjects whose depression had responded to SSRI treatment and found no significant 
difference in mean SUR values between euthymic depressed subjects (versus 26 healthy 
volunteers). These investigators suggested that their observations provided indirect evidence 
that low baseline SERT binding increased (i.e., ‘normalized’) after response to treatment.
Other studies have examined the effects of psychotherapy on SERT binding in depression. 
For example, Viinamýki et al.29 used [123I] β-CIT to examine the effect of dynamic 
psychotherapy on SERT binding in 2 depressed subjects. They reported low baseline SERT 
binding in the prefrontal cortex and thalamus that ‘normalized’ after one year of 
psychotherapy (relative to non-psychotherapy subjects). Martin et al.30 used [99mTc]-
exametazime hexamethylpropyleneamine oxime SPECT to examine regional cerebral blood 
flow (rCBF) in 28 depressed subjects. They found an increase in rCBF in the basal ganglia 
region following response to either interpersonal psychotherapy or venlafaxine therapy. 
Increases in rCBF were observed in the temporal lobe region with venlafaxine and in the 
posterior cingulate gyrus with interpersonal psychotherapy. However, neither of these 
studies employed controlled methodology, and the response to pharmacotherapy was 
superior to interpersonal psychotherapy in both studies.
Finally, several studies used [18F]-fluoro-deoxyglucose (FDG) PET to examine the effect of 
psychotherapy or pharmacotherapy on brain metabolism in depression. Brody et al.31 
studied the relationship between baseline glucose metabolism and response to treatment with 
either interpersonal psychotherapy or paroxetine in 24 depressed subjects. They reported 
that low baseline prefrontal glucose metabolism predicted response to both treatment 
modalities. Goldapple et al.32 examined changes over time in glucose metabolism in 14 
responders to CBT versus 13 responders to paroxetine. Paroxetine responders demonstrated 
an increase in glucose metabolism in the dorsolateral-prefrontal cortex and a reduction in 
glucose metabolism in the hippocampus, while CBT responders showed a reduction in 
glucose metabolism in the dorsolateral-prefrontal cortex and an increase in glucose 
metabolism in the hippocampus and dorsal cingulate regions. These investigators speculated 
that CBT produced a ‘top down’ effect while antidepressants produced a ‘bottom up’ effect, 
with initial change occurring in midbrain neurotransmitter activity.32
We speculate that the current [123I]-ADAM observations may support the notion of 
Goldapple et al.32 of a ‘top-down’ effect of CBT on SERT binding. The mechanism by 
which this physiological process occurs is not well understood. However, the SERT site is 
known to remove excess serotonin from the synaptic cleft,17 and it.is possible that the low 
SERT binding seen during depression may reflect lower brain serotonin levels via a 
compensatory SERT down-regulation. Thus, low SERT binding in depression may reflect an 
overall low serotonin function in depression that “normalizes’ during response to treatment. 
A comparative study of CBT and SSRI therapy with repeated [123I]-ADAM scan sessions 
over time would be necessary to confirm a ‘top down’ (versus ‘bottom up’) effect of CBT.
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Several caveats should be considered when interpreting the current observations. For 
example, it is possible that the increase in low SERT binding in depressed subjects may 
have occurred independently of CBT. As no comparative treatment intervention (e.g., SSRI) 
was included in the current study, it is possible that the observed increase in SERT binding 
occurred as a result of symptom reduction per se or from non-specific aspects of treatment 
(i.e., placebo effect).
The current study did not include comparison groups of depressed subjects who did not 
receive CBT and healthy volunteers who did receive CBT. While the inclusion of these 
groups would have been of heuristic interest, we believe that their inclusion would have 
raised substantial ethical and procedural difficulties. For example, the inclusion of an 
untreated depressed subject group would have been unethical. Moreover, the inclusion of 
healthy volunteers ‘treated’ with CBT would have raised ethical concerns such as exposing 
non-depressed, healthy subjects to a therapy specifically designed to treat depressive 
symptoms with no expected benefit or measurable outcome.
We also note that an increase in SERT binding after treatment occurred in both CBT 
responder and partial and nonresponder groups. This may have resulted from some subjects 
in the partial and nonresponder group having a clinically meaningful reduction in depressive 
symptoms and an increase in SERT binding – despite the fact that these subjects failed to 
achieve a priori criteria for ‘response’. Similarly, it is possible that a larger difference in 
SERT binding between groups would have been more evident had a larger sample size been 
studied, or a different a priori criteria for ‘response’ had been employed.
There was a modest, albeit non-significant, reduction over time in mean SUR values for 
healthy volunteers, and it is possible that this reduction in SERT binding contributed to the 
significance of the increase in SUR values seen in depressed subjects.
It is likely that the change over time in SERT binding occurred gradually and at varying 
rates among depressed subjects. Thus, the change over time in SERT binding in some 
depressed subjects may have lagged behind symptom improvement. As some depressed 
subjects were more severely ill than others, and some subjects did not receive a full course 
of CBT, it is also possible that some of these subjects may have had a more gradual increase 
in SUR values than other depressed subjects. It is also possible that the group differences 
would have been greater had a longer treatment course of CBT been applied.
Other factors may have contributed to variability in the SERT binding results. For example, 
there were differences in the time that elapsed between [123I]-ADAM imaging sessions in 2 
subjects. In addition, we did not control for possible seasonal effects of SERT binding.8 
Although the current study found no influence of age on mean SUR values17, other studies 
have reported an effect of age on SERT binding.1,3
It is possible that comorbid anxiety and/or prior exposure to antidepressant medication could 
have influenced SERT binding18,33, although an exclusion criteria was that patients could 
not have antidepressant medication for at least 12 months. In addition, differences in illness 
length, episode duration, symptom severity, environmental stress, sleep, carbohydrate 
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intake, circadian rhythms, smoking, and alcohol use may also have influenced the current 
SERT binding results.2,8,16,34-38
Finally, it is possible that the current observations occurred by chance alone and were not 
related to treatment response or the degree of symptom improvement. Future placebo-
controlled studies will be needed to determine whether or not treatment response is related 
to change over time in SERT binding in depression.
Conclusion
The findings of the current study suggest that low pre-treatment SERT binding in depression 
may increase over time with treatment response. However, a limited subject sample size and 
large treatment response range hampered our ability to determine whether or not the increase 
over time in SERT binding in depressed subjects was due to treatment response per se. 
Future studies with larger sample sizes will be needed to better determine the relationship 
between SERT binding and treatment in patients with depression.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
SUR values for the right medial temporal lobe for CBT responders, CBT nonresponders, and 
healthy volunteers.
Amsterdam et al. Page 13
J Neuroimaging. Author manuscript; available in PMC 2015 October 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Amsterdam et al. Page 14
Ta
bl
e 
1
D
ep
re
ss
ed
 su
bje
cts
’ d
em
og
rap
hic
 an
d c
lin
ica
l c
ha
rac
ter
ist
ics
.
Su
bje
ct
A
ge
G
en
de
r
A
ge
 1
st
 
Ep
iso
de
Ep
iso
de
 #
*
Ep
iso
de
 D
ur
at
io
n*
*
Pr
e-
C
BT
 H
A
M
-D
Po
st
-C
BT
 H
A
M
-D
1
29
M
20
4
3
20
8
2
39
M
27
5
7
16
4
3
28
M
26
0
3
23
24
4
35
F
14
10
2
21
18
5
62
M
19
6
40
16
8
6
40
M
32
0
96
25
24
7
44
M
40
0
42
16
9
8
28
F
16
4
3
23
6
9
41
M
32
5
6
21
9
10
53
M
15
10
8
19
11
11
26
M
17
1
18
21
21
12
61
M
17
5
7
17
14
13
26
M
15
0
12
0
23
4
14
56
M
16
4
6
22
19
15
31
M
13
0
12
20
6
16
58
M
20
0
3
20
0
17
25
F
25
0
34
19
14
18
33
F
17
1
8
22
7
19
26
M
20
4
30
20
22
20
43
F
20
7
6
21
4
M
ea
n
41
.0
21
.1
3.
3
22
.7
20
.3
11
.6
SD
*
*
*
12
.8
7.
1
3.
3
32
.1
2.
5
7.
4
R
an
ge
25
–6
3
14
-4
0
0-
10
2-
12
0
16
-2
5
4-
24
*
Ep
iso
de
 #
 =
 N
um
be
r o
f p
rio
r m
ajo
r d
ep
res
siv
e d
iso
rde
r e
pis
od
es
*
*
Ep
iso
de
 d
ur
at
io
n 
= 
D
ur
at
io
n 
in
 m
on
th
s o
f t
he
 c
ur
re
nt
 m
ajo
r d
ep
res
siv
e d
iso
rde
r e
pis
od
e
*
*
*
SD
 =
 S
ta
nd
ar
d 
de
vi
at
io
n
J Neuroimaging. Author manuscript; available in PMC 2015 October 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Amsterdam et al. Page 15
Table 2
Healthy volunteers’ demographic and clinical characteristics.
Subject Age Gender HAM-D Score #1 HAM-D Score #2
1 34 F 2 2
2 53 F 0 0
3 56 F 0 0
4 40 M 0 0
5 48 M 1 1
6 26 M 0 0
7 36 M 0 0
8 62 M 0 0
9 47 M 0 0
10 46 M 0 0
Mean 44.8 - 0.3 0.3
SD 10.93 - 0.7 0.7
Range 20-62 - 0-1 0-2
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